|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 49, 217-229, January 2008 Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice
* Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, and Child and Family Research Institute, Vancouver, British Columbia, Canada V5Z 4H4 Published, JLR Papers in Press, October 24, 2007.
1 To whom correspondence should be addressed. e-mail: mrh{at}cmmt.ubc.ca A combination of the interrelated metabolic risk factors obesity, insulin resistance, dyslipidemia, and hypertension, often described as the "metabolic syndrome," is known to increase the risk of developing cardiovascular disease and diabetes. Stearoyl-coenzyme A desaturase (SCD) activity has been implicated in the metabolic syndrome, but detailed studies of the beneficial metabolic effects of SCD deficiency have been limited. Here, we show that absence of the Scd1 gene product reduces plasma triglycerides and reduces weight gain in severely hyperlipidemic low density lipoprotein receptor (LDLR)-deficient mice challenged with a Western diet. Absence of SCD1 also increases insulin sensitivity, as measured by intraperitoneal glucose and insulin tolerance testing. SCD1 deficiency dramatically reduces hepatic lipid accumulation while causing more modest reductions in plasma apolipoproteins, suggesting that in conditions of sustained hyperlipidemia, SCD1 functions primarily to mediate lipid stores. In addition, absence of SCD1 partially ameliorates the undesirable hypertriglyceridemic effect of antiatherogenic liver X receptor agonists. Our results demonstrate that constitutive reduction of SCD activity improves the metabolic phenotype of LDLR-deficient mice on a Western diet.
Supplementary key words monounsaturated fatty acids very low density lipoprotein high density lipoprotein apolipoprotein B mouse model liver atherosclerosis ATP binding cassette transporter A1 hyperlipidemia Western diet low density lipoprotein receptor coenzyme A Abbreviations: ACC-1, acetyl-coenzyme A carboxylase-1; apoE, apolipoprotein E; FH, familial hypercholesterolemia; FPLC, fast-protein liquid chromatography; HTG, hypertriglyceridemia; LDLR, low density lipoprotein receptor; LXR, liver X receptor; SCD, stearoyl-coenzyme A desaturase; SREBP-1, sterol-regulatory element binding protein-1; TC, total cholesterol; TG, triglyceride
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||